By Fineline Cube Pfizer Inc. (NYSE: PFE) and Valneva SE (NASDAQ: VALN) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF‑07307405, the companies’ 6‑valent outer surface protein A (OspA)‑based Lyme disease vaccine candidate. EMA validation confirms the submission is administratively complete and formally starts the centralized review procedure.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Medicines Agency (EMA) |
| Submission Type | Marketing Authorization Application (MAA) – validated |
| Product | PF‑07307405, 6‑valent OspA‑based Lyme disease vaccine candidate |
| Target Population | Individuals aged 5 years and older |
| Announcement Date | 14 Aug 2026 |
| Next Steps | Centralized EMA scientific review; potential CHMP opinion |
Vaccine Profile & Mechanism of Action
- Molecule: PF‑07307405, a 6‑valent vaccine based on outer surface protein A (OspA) of Borrelia burgdorferi sensu lato, the causative pathogen of Lyme disease
- Design: Targets six OspA serotypes, designed to provide broad coverage against the Borrelia strains most prevalent in both North America and Europe
- Partnership Structure: Under an April 2020 collaboration and license agreement, Pfizer and Valneva co‑develop PF‑07307405; assuming regulatory success, Pfizer will exclusively manufacture and commercialize the vaccine
- Unmet Need: No Lyme disease vaccine is currently approved for humans, making PF‑07307405 a potential first‑in‑class preventive option
Clinical Evidence – Phase 3 VALOR Trial
| Element | Detail |
|---|---|
| Trial Name | VALOR – “Vaccine Against Lyme for Outdoor Recreationists” |
| Identifier | NCT05477524 |
| Primary Readout | Efficacy of more than 70 % observed against Lyme disease cases |
| Population | Individuals aged 5 years and older |
| Safety | Well tolerated; no safety concerns identified |
The Phase 3 VALOR study investigated whether PF‑07307405 prevents Lyme disease cases in a broad at‑risk population. The observed efficacy of more than 70 % combined with a clean tolerability profile forms the core of the MAA dossier.
Market Impact & Outlook
- First‑Mover Potential: With no licensed human Lyme disease vaccine on the market, a successful approval would create a new preventive category, with demand concentrated in endemic regions across North America and Europe.
- Addressable Population: The 5‑plus age indication and outdoor‑recreation positioning open a broad target cohort, from children in endemic areas to adult hikers, hunters, and forestry workers.
- Commercial Leverage: Pfizer’s exclusive manufacturing and commercialization rights give it direct control over launch execution, building on its established global vaccine infrastructure.
- Strategic Significance: Validation by the EMA moves the program closer to a potential first approval, while parallel regulatory pathways in the United States would further expand the commercial opportunity for the Pfizer–Valneva partnership.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory review timelines, clinical outcomes, and commercial expectations for PF‑07307405. Actual results may differ due to risks including regulatory decisions, market adoption, and competitive dynamics.-Fineline Info & Tech